Adenosine augmentation therapy for epilepsy

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Deficiency of the brain's endogenous anticonvulsant adenosine is a pathologic hallmark of epilepsy. Consequently, focal adenosine augmentation therapies (AATs) constitute a rational approach for seizure suppression. Focal adenosine augmentation and resulting seizure suppression can be realized by implanting adenosine-releasing stem cells or polymers into epileptogenic brain regions. For an expanded treatment of this topic see Jasper's basic mechanisms of the epilepsies. 4th ed. (Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV, eds) published by Oxford University Press (available on the National Library of Medicine Bookshelf [NCBI] at).

Original languageEnglish (US)
Pages (from-to)97
Number of pages1
Issue numberSUPPL. 5
StatePublished - Dec 2010
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology


  • Adenosine kinase
  • Adenosine-releasing polymers
  • Anticonvulsant
  • Astrogliosis
  • RNA interference
  • Seizures
  • Stem cells


Dive into the research topics of 'Adenosine augmentation therapy for epilepsy'. Together they form a unique fingerprint.

Cite this